Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 7/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19601113 | 0.94 | CYP1A1 (0.35) | ACHESMN1; SMN2MAPK1LMNAPKM | |
| SCHEMBL19607292 | 0.87 | CYP1A1 (0.39) | ACHESMN1; SMN2PKMBCHEL3MBTL1 | |
| SCHEMBL19601080 | 0.83 | LMNA (0.31) | SMN1; SMN2LMNAHTTALDH1A1KMT2A | |
| SCHEMBL19601105 | 0.82 | ACHE (0.55) | ACHEBCHEALDH1A1IDO1 | |
| SCHEMBL19601086 | 0.82 | FFAR4 (0.36) | ACHESMN1; SMN2LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL19601120 | 0.79 | ACHE (0.54) | ACHEBCHEALDH1A1IDO1 | |
| SCHEMBL19607289 | 0.76 | ACHE (0.43) | ACHEBCHEIDO1 | |
| SCHEMBL19601115 | 0.76 | ACHE (0.51) | ACHEBCHEALDH1A1 | |
| SCHEMBL19607239 | 0.75 | L3MBTL1 (0.36) | ACHESMN1; SMN2PKML3MBTL1ALDH1A1 | |
| SCHEMBL19601116 | 0.74 | ACHE (0.58) | ACHESMN1; SMN2BCHEALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10310350-B2 | Organic compound, electrochromic compound, and electrochromic element, optical filter, lens unit, imaging device, and window component having same | CANON KABUSHIKI KAISHA (JP) | 2019-06-04 | — | — | US | disclosed |
| US-20170329195-A1 | ORGANIC COMPOUND, ELECTROCHROMIC COMPOUND, AND ELECTROCHROMIC ELEMENT, OPTICAL FILTER, LENS UNIT, IMAGING DEVICE, AND WINDOW COMPONENT HAVING SAME | CANON KABUSHIKI KAISHA (JP) | 2017-11-16 | — | — | US | disclosed |
| US-20170329195-A1 | ORGANIC COMPOUND, ELECTROCHROMIC COMPOUND, AND ELECTROCHROMIC ELEMENT, OPTICAL FILTER, LENS UNIT, IMAGING DEVICE, AND WINDOW COMPONENT HAVING SAME | CANON KABUSHIKI KAISHA (JP) | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10310350-B2 | Organic compound, electrochromic compound, and electrochromic element, optical filter, lens unit, imaging device, and window component having same | KCNJ2, KCNH3, KCNN2 | ACHE 416/4885SMN1; SMN2 4088/4885MAPK1 1414/4885 |
| US-20170329195-A1 | ORGANIC COMPOUND, ELECTROCHROMIC COMPOUND, AND ELECTROCHROMIC ELEMENT, OPTICAL FILTER, LENS UNIT, IMAGING DEVICE, AND WINDOW COMPONENT HAVING SAME | KCNJ2, KCNH3, KCNN2 | ACHE 416/4885SMN1; SMN2 4088/4885MAPK1 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.